Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Quality of Life Under Immunotherapies in Elderly Patients With Advanced Melanoma or NSCLC
NCT03673332Phase 4Terminated
- Sponsor
- Institut Paoli-Calmettes
- Start
- Oct 2019
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in melanoma and non-small cell lung cancer (NSCLC), sponsored by Institut Paoli-Calmettes. Primary endpoints: Number of participants with adverse events as assessed by CTCAE v5.0 up to 24 months and EORTC QLQ-C30 and QLQ-ELD14 total score up to 24 months. Started Oct 2019; status: terminated.
02
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03673332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673332.